Yoshitaka Okamoto - Concepedia

Author

Yoshitaka Okamoto

Also Known As

K. Ohta, Okamoto Yoshitaka, R. N. Naclerio, R. Naclerio, Y OKAMOTO, Y Okamoto, Y. OKAMOTO, Y. Okamoto, YOSHITAKA OKAMOTO, Yoshitaka OKAMOTO

463

Publications

17.7K

Citations

H-Index

231

Concepts

All Affiliations

Chiba University Chiba University Hospital Charité - Universitätsmedizin Berlin Nippon Medical School Universidade do Porto

About

Yoshitaka Okamoto is an author at Chiba University specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	74	4.6K
2	Health Sciences	12	13	739
3	Engineering	5	5	182
4	Arts	1	1	34
5	Education	1	1	39

Yoshitaka Okamoto

173

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs Jean Bousquet, Holger J. Schünemann, Bolesław Samoliński, Journal of Allergy and Clinical Immunology AsthmaAllergyAllergy MedicineFuture NeedsAllergic Rhinitis	2012	628
A Phase I Study of<i>In vitro</i>Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer Shinichiro Motohashi, Aki Ishikawa, Eiichi Ishikawa, Clinical Cancer Research	2006	239
The Interleukin-33-p38 Kinase Axis Confers Memory T Helper 2 Cell Pathogenicity in the Airway Yusuke Endo, Kiyoshi Hirahara, Tomohisa Iinuma, Immunity AsthmaInflammationCytokineInflammatory Lung DiseaseCell Pathogenicity	2015	222
Amphiregulin-Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis Yuki Morimoto, Kiyoshi Hirahara, Masahiro Kiuchi, Immunity AsthmaInflammationCytokineAnti-inflammatorySignal Transduction	2018	211
Results of carbon ion radiotherapy for head and neck cancer Jun-etsu Mizoe, Azusa Hasegawa, Keiichi Jingu, Radiotherapy and Oncology Adaptive RadiotherapyRadiation TherapyMedicineCarbon Ion RadiotherapyBrachytherapy	2012	200
Combination therapy of <i>in vitro</i>‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma Naoki Kunii, S. Horiguchi, Shinichiro Motohashi, Cancer Science Cell TherapyImmunologyImmunoeditingPathologyMetronomic Chemotherapy	2009	181
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy Kazuki Yamasaki, S. Horiguchi, Motoyoshi Kurosaki, Clinical Immunology Radiation OncologyTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor	2010	178
miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma Nijiro Nohata, Yaeko Sone, Toyoyuki Hanazawa, Oncotarget	2011	178
Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer Tetsuro Uchida, S. Horiguchi, Yuriko Tanaka, Cancer Immunology Immunotherapy Radiation OncologyCancer ImmunosurveillanceNasal SubmucosaMedicineImmunology	2007	158
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC) Naoko Kikkawa, Toyoyuki Hanazawa, Lisa Fujimura, British Journal of Cancer	2010	154

Page 1